

3-7-05

ifw

Express Mail No. EV452774470US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dingivan *et al.*

Confirmation No.: 3565

Serial No.: 10/657,006

Art Unit: 1614

Filed: September 5, 2003

Examiner: To Be Assigned

FOR: METHODS OF PREVENTING
OR TREATING T CELL
MALIGNANCIES BY
ADMINISTERING CD2
ANTAGONISTS

Attorney Docket No: 10271-116-999

REQUEST FOR CORRECTION OF UPDATED FILING RECEIPT

Office of Initial Patent Examiner
Filing Receipt Corrections
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed please find the original and one copy of the Updated Filing Receipt mailed September 22, 2004 in connection with the above-identified application. Please note the correction in red ink on the enclosed copy of the Updated Filing Receipt. Specifically, "Meil Zhang, Bethesda, MD" should be substituted with "Meili Zhang, Bethesda, MD".

Applicants respectfully request that the United States Patent and Trademark Office issue a Corrected Filing Receipt setting forth the correct spelling of Meili Zhang.

It is estimated that no fee is required for correction of the Updated Filing Receipt. However, should the Commissioner determine that a fee is due, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: March 4, 2005

Margaret B. Brivanlou 40,922
Margaret B. Brivanlou (Reg. No.)

By: Lyndanguyen 54,338
Lynda Q. Nguyen (Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939




UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/657,006	09/05/2003	1614	2918	10271-116-999	6	44	13

20583
 JONES DAY
 222 EAST 41ST ST
 NEW YORK, NY 10017



CONFIRMATION NO. 3565

UPDATED FILING RECEIPT



OC000000013858950

Date Mailed: 09/22/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Christine Dingivan, Gaithersburg, MD;
 Thomas Waldmann, Silver Spring, MD;
 Zhuo Zhang, Clarksburg, MD;
 Meili Zhang, Bethesda, MD;

Meili

Power of Attorney: None**Domestic Priority data as claimed by applicant**

This appln claims benefit of 60/409,024 09/05/2002
 and claims benefit of 60/410,385 09/12/2002

Foreign Applications**If Required, Foreign Filing License Granted:** 01/21/2004

The number of your priority application, to be used for filing abroad under the Paris Convention is,
US10/657,006

Projected Publication Date: 12/30/2004**Non-Publication Request:** No

Early Publication Request: No

Title

Methods of preventing or treating T cell malignancies by administering CD2 antagonists

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/657,006	09/05/2003	1614	2918	10271-116-999	6	44	13

20583
 JONES DAY
 222 EAST 41ST ST
 NEW YORK, NY 10017



CONFIRMATION NO. 3565

UPDATED FILING RECEIPT



OC000000013858950

Date Mailed: 09/22/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Christine Dingivan, Gaithersburg, MD;
 Thomas Waldmann, Silver Spring, MD;
 Zhuo Zhang, Clarksburg, MD;
 Meill Zhang, Bethesda, MD;

Power of Attorney: None

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/409,024 09/05/2002
 and claims benefit of 60/410,385 09/12/2002

Foreign Applications

If Required, Foreign Filing License Granted: 01/21/2004

The number of your priority application, to be used for filing abroad under the Paris Convention is,
US10/657,006

Projected Publication Date: 12/30/2004

Non-Publication Request: No

Early Publication Request: No

Title

Methods of preventing or treating T cell malignancies by administering CD2 antagonists

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).